(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 28.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.78%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Omniab's revenue in 2026 is $28,939,000.On average, 9 Wall Street analysts forecast OABI's revenue for 2026 to be $4,555,473,350, with the lowest OABI revenue forecast at $4,262,193,823, and the highest OABI revenue forecast at $4,842,953,974. On average, 8 Wall Street analysts forecast OABI's revenue for 2027 to be $6,817,915,418, with the lowest OABI revenue forecast at $4,262,193,823, and the highest OABI revenue forecast at $10,759,574,868.
In 2028, OABI is forecast to generate $8,887,978,873 in revenue, with the lowest revenue forecast at $5,540,851,969 and the highest revenue forecast at $13,852,129,923.